HAEMATO AG Stock Xetra

Equities

HAEK

DE000A289VV1

Pharmaceuticals

Market Closed - Xetra 11:36:27 2024-02-29 am EST 5-day change 1st Jan Change
21.4 EUR -1.83% Intraday chart for HAEMATO AG -.--% -23.02%
3 months-17.69%
6 months+3.88%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2023 * 270M 290M Sales 2024 * 281M 303M Capitalization 90.96M 97.93M
Net income 2023 * 7M 7.54M Net income 2024 * 9M 9.69M EV / Sales 2023 * 0.26 x
Net cash position 2023 * 21.3M 22.93M Net cash position 2024 * 24.3M 26.16M EV / Sales 2024 * 0.24 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 76
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.83%
3 months-17.69%
6 months+3.88%
Current year-23.02%
More quotes
Current year
20.00
Extreme 20
28.00
1 year
17.40
Extreme 17.4
28.00
3 years
13.65
Extreme 13.65
30.00
5 years
13.65
Extreme 13.65
50.80
10 years
13.65
Extreme 13.65
71.99
More quotes
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW